Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer
European Journal of Cancer · 2024
DOI: 10.1016/j.ejca.2024.114145 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Andrew Dj Pearson und 42 weiteren Autor:innen. Beteiligte Einrichtung: ACCELERATE, Europe, Belgium. Electronic address: andy1pearson@btinternet.com. Hauptthemen laut MEDLINE: Neoplasms, Glycogen Synthase Kinase 3 beta, Proto-Oncogene Proteins c-akt, TOR Serine-Threonine Kinases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Rally Foundation, National Brain Tumor Society.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Phosphatidylinositol 3-kinase (PI3-K) signalling pathway is a crucial path in cancer for cell survival and thus represents an intriguing target for new paediatric anti-cancer drugs. However, the unique clinical toxicities of targeting this pathway (resulting in hyperglycaemia) difficulties combining with chemotherapy, rarity of mutations in childhood tumours and concomitant mutations have resulted in major barriers to clinical translation of these inhibitors in treating both adults and children. Mutations in PIK3CA predict response to PI3-K inhibitors in adult cancers. The same mutations occur in children as in adults, but they are significantly less frequent in paediatrics. In children, high-grade gliomas, especially diffuse midline gliomas (DMG), have the highest incidence of PIK3CA mutations. New mutation-specific PI3-K inhibitors reduce toxicity from on-target PI3-Kα wild-type activity. The mTOR inhibitor everolimus is approved for subependymal giant cell astrocytomas. In paediatric cancers, mTOR inhibitors have been predominantly evaluated by academia, without an overall strategy, in empiric, mutation-agnostic clinical trials with very low response rates to monotherapy. Therefore, future trials of single agent or combination strategies of mTOR inhibitors in childhood cancer should be supported by very strong biological rationale and preclinical data. Further preclinical evaluation of glycogen synthase kinase-3 beta inhibitors is required. Similarly, even where there is an AKT mutation (∼0.1 %), the role of AKT inhibitors in paediatric cancers remains unclear. Patient advocates strongly urged analysing and conserving data from every child participating in a clinical trial. A priority is to evaluate mutation-specific, central nervous system-penetrant PI3-K inhibitors in children with DMG in a rational biological combination. The choice of combination, should be based on the genomic landscape e.g. PTEN loss and resistance mechanisms supported by preclinical data. However, in view of the very rare populations involved, innovative regulatory approaches are needed to generate data for an indication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ACCELERATE, Europe, Belgium. Electronic address: andy1pearson@btinternet.com.
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, USA.
- Childrens' Hospital, CO, USA.
- ACCELERATE, Europe, Belgium.
- US Food and Drug Administration, Silver Springs, MD, USA.
- Children's Cancer Cause, Washington, DC, USA.
Förderung
- NCI NIH HHS
- Rally Foundation
- National Brain Tumor Society
- Leukemia and Lymphoma Society
- Pediatric Brain Tumor Foundation
- Dana-Farber Cancer Institute
- Boston Children's Hospital
- Andrew McDonough B+ Foundation
Zitieren
APA
Pearson, A. D., DuBois, S. G., Macy, M. E., de Rojas, T., Donoghue, M., Weiner, S., Knoderer, H., Bernardi, R., Buenger, V., Canaud, G., Cantley, L., Chung, J., Fox, E., Friend, J., Glade-Bender, J., Gorbatchevsky, I., Gore, L., Gupta, A., Hawkins, D. S., …, & Vassal, G. (2024). Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114145
Vancouver
Pearson AD, DuBois SG, Macy ME, de Rojas T, Donoghue M, Weiner S, et al. Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114145
BibTeX
@article{Pearson2024,
author = {Pearson, Andrew Dj and DuBois, Steven G and Macy, Margaret E and de Rojas, Teresa and Donoghue, Martha and Weiner, Susan and Knoderer, Holly and Bernardi, Ronald and Buenger, Vickie and Canaud, Guillaume and Cantley, Lewis and Chung, John and Fox, Elizabeth and Friend, John and Glade-Bender, Julia and Gorbatchevsky, Igor and Gore, Lia and Gupta, Abha and Hawkins, Douglas S and Juric, Dejan and Lang, Leigh Anna and Leach, Danielle and Liaw, Danny and Lesa, Giovanni and Ligas, Franca and Lindberg, Gavin and Lindberg, Wendy and Ludwinski, Donna and Marshall, Lynley and Mazar, Andrew and McDonough, Joe and Nysom, Karsten and Ours, Christopher and Pappo, Alberto and Parsons, D William and Rosenfeld, Amy and Scobie, Nicole and Smith, Malcolm and Taylor, Danielle and Weigel, Brenda and Weinstein, Amy and Karres, Dominik and Vassal, Gilles},
title = {Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer},
journal = {European Journal of Cancer},
year = {2024},
doi = {10.1016/j.ejca.2024.114145}
}
EUVIMED